#TITLE_ALTERNATIVE#
One of the causes of interindividual pharmacokinetic variation is genetic polymorphism of drug enzyme metabolizer, known as cytochrome P450 (CYP). CYP2C9*3 variant is the most frequent allele from CYP2C9 in the previous researches and known having function in the drugs metabolism, which one of them...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/10748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | One of the causes of interindividual pharmacokinetic variation is genetic polymorphism of drug enzyme metabolizer, known as cytochrome P450 (CYP). CYP2C9*3 variant is the most frequent allele from CYP2C9 in the previous researches and known having function in the drugs metabolism, which one of them is irbesartan. The purpose of this research is to know the relationship between pharmacokinetic of irbesartan and the existence of CYP2C9*3 allele variant. Irbesartan pharmacokinetic parameter is obtained from irbesartan tablet bioequivalence test. CYP2C9*3 allele is identified by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method, and characterized by migration analysis with polyacrylamide gel. Pharmacokinetic data shows that are large interindividual variations of irbesartan. The half-life eliminations are varied from 5, 28 hours to 19, 336 hours. From this pharmacogenetic study, all subjects only show one band with 101 base pairs(bps) in size, which means that CYP2C9*3 allele variant was not found in the population studied. Interindividual pharmacokinetic variation are not able to be defined by the existence of CYP2C9*3 allele. <br />
|
|---|